Cells producing antibody compositions with increased antibody dependent cytotoxic activity

• US 6,946,292 B2
• Filed: 10/09/2001
• Issued: 09/20/2005
• Est. Priority Date: 10/06/2000
• Status: Expired due to Term

• Current Assignee: Kyowa Kirin Co., Ltd. (Kirin Holdings Company Limited)
• Original Assignee: Kyowa Hakko Kogyo Company Limited (Kirin Holdings Company Limited)
• Inventors: Shinkawa, Toyohide, Yamane, Naoko, Uchida, Kazuhisa, Yamasaki, Motoo, Yamano, Kazuya, Satoh, Mitsuo, Nakamura, Kazuyasu, Hanai, Nobuo, Kanda, Yutaka, Hosaka, Emi
• Primary Examiner(s): Webhe, Anne M.
• Assistant Examiner(s): Kelly, Robert M.
• Application Number:
  US09/971,773
• Publication Number:
  US 20030115614A1
• Time in Patent Office: 1,442 Days
• Field of Search: 800/8, 435/326, 435/70.1, 435/183, 435/232
• US Class Current: 435/326
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: C07K 16/1063 env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 16/241 Tumor Necrosis Factors
• CPC Class Codes: C07K 16/2812 against CD4
• CPC Class Codes: C07K 16/2863 against receptors for growth factors, growth regulators
• CPC Class Codes: C07K 16/2866 against receptors for cytokines, lymphokines, interferons
• CPC Class Codes: C07K 16/2887 against CD20
• CPC Class Codes: C07K 16/2896 against molecules with a "CD"-designation, not provided for elsewhere
• CPC Class Codes: C07K 16/3084 against tumour-associated gangliosides
• CPC Class Codes: C07K 16/32 against translation products of oncogenes
• CPC Class Codes: C07K 16/44 against material not provided for elsewhere , e.g. haptens, metals, DNA, RNA, amino acids
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/41 Glycosylation, sialylation, or fucosylation
• CPC Class Codes: C07K 2317/565 : Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/732 : Antibody-dependent cellular cytotoxicity [ADCC]
• CPC Class Codes: C07K 2319/30 : Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
• CPC Class Codes: C12N 15/8245 : involving modified carbohydrate or sugar alcohol metabolism, e.g. starch biosynthesis
• CPC Class Codes: C12N 15/8257 : for the production of primary gene products, e.g. pharmaceutical products, interferon
• CPC Class Codes: C12N 15/8258 : for the production of oral vaccines (antigens) or immunoglobulins
• CPC Class Codes: C12N 9/0006 : acting on CH-OH groups as donors (1.1)
• CPC Class Codes: C12N 9/1051 : Hexosyltransferases (2.4.1)
• CPC Class Codes: C12N 9/90 : Isomerases (5.)
• CPC Class Codes: C12P 21/00 : Preparation of peptides or proteins single cell protein C12N1/00
• CPC Class Codes: C12P 21/005 : Glycopeptides, glycoproteins
• CPC Class Codes: C12Y 204/01068 : Glycoprotein 6-alpha-L-fucosyltransferase (2.4.1.68), i.e. FUT8

Abstract

The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.

Claims

1. An isolated fucosyltransferase knock-out host cell wherein when a gene encoding an antibody molecule is introduced in to said host cell, said host cell produces an antibody composition comprising the antibody molecule,

said host cell being a mammalian cell,

said antibody molecule comprising a Fc region comprising complex N-glycoside-linked sugar chains bound to the Fc region,

said sugar chains comprising a reducing end which contains an N-acetylglucosamine, wherein the sugar chains do not contain fucose bound to the 6 position of N-acetylglucosamine in the reducing end of the sugar chains.

2. The isolated host cell of claim 1, wherein said host cell is a CHO cell.

3. The isolated host cell of claim 1, wherein said host cell is a NS0 cell.

4. The isolated host cell of claim 1, wherein said host cell is a SP2/0 cell.

5. The isolated host cell of claim 1, wherein said host cell is a YB2/0 cell.

6. The isolated host cell of claim 1, wherein said antibody molecule is an IgG antibody.

7. An isolated fucosyltransferase knock-out host cell comprising a gene encoding an antibody molecule, wherein said host cell produces an antibody composition comprising the antibody molecule,

said host cell being a mammalian cell,

said antibody molecule comprising a Fc region comprising complex N-glycoside-linked sugar chains bound to the Fc region,

said sugar chains comprising a reducing end which contains an N-acetylglucosamine, wherein the sugar chains do not contain fucose bound to the 6 position of N-acetylglucosamine in the reducing end of the sugar chains.

8. The isolated host cell of claim 7, wherein said host cell is a CHO cell.

9. The isolated host cell of claim 7, wherein said host cell is a NS0 cell.

10. The isolated host cell of claim 7, wherein said host cell is a SP2/0 cell.

11. The isolated host cell of claim 7, wherein said host cell is a YB2/0 cell.

12. The isolated host cell of claim 7, wherein said antibody molecule is an lgG antibody.